Abstract: Objective To investigate the effect of insulin glargine combined with glimepiride on glycemic control and serum levels of cysteine-rich acidic protein （SPARC） in elderly patients with type 2 diabetes. Methods One hundred and twenty six patients with type 2 diabetes were randomly divided into control group and observation group on average. The patients in the control were given glargine treatment while those in observation group received both insulin glargine and glimepiride. Fasting blood glucose （FBG）,2 hour postprandial blood glucose （2 hPG）,HbA1c,and SPARC levels were compared between the two groups before and after 3 months of treatments. The effects and adverse reactions of the two groups of patients were compared. Results The effective rate was 79.4% in the control and 90.5% in the observation group after treatments （P<0.05）. No significant difference of FBG,2 hPG,HBA1C and SPARC levels was seen between the two groups before treatment （P>0.05）. After treatment,however,the levels of FBG,2 hPG,HBA1C,and SPARC in the two groups were significantly decreased （P<0.05）. No hypoglycemia occurred in all of the patients. Conclusion The therapeutic effect of insulin glargine combined with glimepiride is promising in glycemic control of elderly patients with type 2 diabetes,which may reduce insulin resistance in diabetic patients with high safety.

Key words: Insulin glargine, Glimepiride, Type 2 diabetes, Cysteine-rich acidic secretory protein